The expression levels of a circulating extracellular domain of HER-2 can be detected in the plasma and serum of patients with metastatic breast cancer using an enzyme immunoassay (ELISA) method. In this study, we evaluated the clinical significance of high and low levels of HER-2 in the plasma of 46 patients with metastatic breast cancer enrolled in a clinical trial of high-dose chemotherapy (HDCT) using cyclophosphamide, mitoxantrone, and paclitaxel with autologous stem cell transplantation (ASCT). Using 2500 U/ml as the cut-point, 20 patients (46%) had elevated HER-2 levels (HER-2 positive). Our results suggest that patients with metastatic breast cancer and high soluble plasma HER-2 have a significantly poorer overall (OS) and progression-free survival (PFS) following high-dose chemotherapy with paclitaxel and ASCT. The median OS of patients with low levels of HER-2 was significantly longer (P Ͻ 0.01) than the median OS of patients with high levels of HER-2 (29.8 months vs 15.9 months). PFS was also significantly longer (P Ͻ 0.01) for patients who were HER-2-negative, than for patients who were HER-2-positive (13.0 vs 8.6 months). Univariate analysis showed that patients with liver or lung metastases had significantly reduced OS and PFS. Patients with metastases to two or more sites also had a significantly reduced time to disease progression, but not OS. In multivariable analysis, lung metastases contributed along with HER-2-positive status to determine a group of patients with significantly poorer OS. However, HER-2-positive status remained the only independent predictor of PFS. Bone Marrow Transplantation (2001) 27, 847-853.
The receptor tyrosine kinase, HER-2, is overexpressed and/or the HER-2 gene is amplified in approximately 30% of breast and ovarian cancers and in other cancers such as lung, bladder and kidney. [1] [2] [3] Overexpression of the HER-2 proto-oncogene in patients with node-positive and nodenegative breast cancer correlates with a poorer response and a reduced overall and progression-free survival in patients treated with hormone therapy, adjuvant radiotherapy, adjuvant and high-dose chemotherapy treatment regimens. [4] [5] [6] [7] [8] In general, HER-2 overexpression predicts for poor prognosis in breast cancer.
The main treatments for patients with metastatic breast cancer, conventional chemotherapy and the experimental treatment with high-dose chemotherapy, offer only some survival benefit to this group of patients. As a result, interest in the use of a relatively new group of drugs, the taxanes, paclitaxel (taxol; TXL) and docetaxel in various treatment regimens has been generated. In vitro and phase I/II clinical treatment studies indicate that these drugs may be active agents against metastatic breast cancer. [9] [10] [11] [12] The purpose of this study was to examine the expression levels of plasma HER-2 in 46 patients with metastatic breast cancer undergoing high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). These patients were participants in a phase I/II trial using the cytotoxic drug paclitaxel (taxol; TXL) in a high-dose chemotherapy regimen. 13 Since the effectiveness of HDCT with ASCT for the treatment of metastatic breast cancer remains experimental and controversial, the evaluation of various prognostic and/or predictive factors which may identify patients who may benefit from HDCT would be of great interest.
In this study, the expression levels of the HER-2 extracellular (ligand binding) domain in the plasma of these patients was determined using a human HER-2/neu quantitative ELISA. High levels of plasma HER-2 were found to correlate with poorer overall and progression-free survival. These results support our earlier findings on the prognostic power of HER-2 in the HDCT treatment of patients with metastatic breast cancer.
Patients and methods

Patient population
Forty-six (46) patients, enrolled in a phase I/II clinical trial, who completed a HDCT treatment regimen using cyclophosphamide, mitoxantrone, and paclitaxel with autologous blood stem cell support were included in this study. 13 The clinical trial and HER-2 study was approved by the institutional review board and informed consent was obtained from all patients.
All patients were female, median age 47, (range 29-56) with histologically proven metastatic breast cancer (stage IV). To be eligible, patients could not have been treated with chemotherapy for metastatic breast cancer or had been treated with adjuvant chemotherapy at least 6 months before study entry. Patients were either hormone receptor negative, had progressed on hormone therapy or had rapidly progressing disease where a response to hormone treatment could not be anticipated. Karnofsky performance status of 60% or more was required. Patients who had measurable or evaluable lesions and patients with nonevaluable disease (NED) were included in both phase I and II portions of the study. Information on age, previous hormone treatment, and metastatic sites was available for this group of patients. Information on hormone receptor status was available for a reduced subset of this group (n = 39 for estrogen receptor and n = 37 for progesterone receptor). 
Chemotherapy
HER-2 quantitation of plasma samples
HER-2 plasma levels were quantified using the human HER-2/neu quantitative ELISA kit from Oncogene Research Products (Cambridge, MA, USA). This is a sandwich enzyme immunoassay utilizing a mouse monoclonal antibody for capture and a rabbit polyclonal serum for the detection of the human HER-2 protein. Both capture and detection reagents specifically bind to the extracellular domain of the HER-2 protein. Bloods samples (5 ml, EDTA collection tube) were collected at various times during patient treatment. In this study, soluble HER-2 levels in patient plasma obtained from peripheral blood samples drawn (5 ml, EDTA collection tube) were analyzed on day 1 or day 2 of the apheresis collection of autologous blood stem cell product, following induction chemotherapy as described in Chemotherapy. Plasma was obtained by centrifugation of the peripheral blood samples at 200 g, for 10 min. Plasma samples were stored at −80°C. Prior to assay, samples were thawed and centrifuged for 10 min at 14 000 g at 4°C. The supernatant was diluted 50-fold in the provided sample diluent which contained normal mouse serum according to the manufacturer's instructions (Oncogene). Plasma samples were obtained from the peripheral blood of 10 normal healthy female donors to initially define an overexpression cut-point for HER-2.
Statistical analysis
HER-2 status (positive or negative) was determined by defining a cut-point (2500 U/ml) that provided the maximum separation of Kaplan-Meier survivor curves based on overall survival. Patients with plasma HER-2 levels equal or greater than 2500 U/ml were defined to be HER-2-positive or overexpressed HER-2.
The association between HER-2-positive status (both as a dichotomous and a continuous variable) and clinicopathological variables was investigated using the Pearson test for association (2 × n tables) or Fisher's exact test for association (2 × 2 tables). Survival was estimated using the Kaplan-Meier product limit estimate 14 of the survivorship function. Overall survival (OS) was defined as the time (months) from study enrolment until death from metastatic disease or censorship. Progression-free survival (PFS) was defined as the time (months) from study enrolment until documented progression of metastatic disease or censorship. Comparisons of survival by HER-2 status (positive and negative) were conducted using the log-rank test.
Cox proportional hazard regression models 15 defined hazard ratios (HR) and 95% confidence intervals (CI). HR and 95% CI were calculated for each independent variable, for the endpoints of OS and PFS. Additionally, for both OS and PFS, variables with HR that were shown to be significant at 5% or better were entered into a final regression model. Estimates from this model provided HR and 95% CI adjusted for all other variables in the model.
Results
HER-2 expression and clinical and pathological characteristics
A total of 46 patients were available for analysis. The median age was 47 years (range 29-56). During the followup period of 64 months, (range, 31-64 months), 43 of 46 patients (94%) experienced progression of metastatic disease and 37 of 46 patients (80%) died due to metastatic breast cancer. The time at risk for death varied from 4.8 to 63.0 months. The time at risk for disease progression varied from 1.6 to 63.0 months.
Following induction chemotherapy and prior to HDCT, eight patients had complete response (CR), 25 patients had a partial response (PR) and 11 patients had stable disease (SD). One patient had nonevaluable disease and response information was not available for one patient. The response to induction chemotherapy did not predict clinical outcome (data not shown) and 38% (3/8) patients with CR, 32% (8/25) patients with PR and 73% (8/11) patients with SD had high levels of soluble HER-2.
The results of tests of association between HER-2 positive status and clinicopathological characteristics are listed in Table 1 . None of these variables was significantly associated with HER-2-positive status (HER-2 Ͼ2500 U/ml). No association was found between elevated levels of HER-2 and age, previous hormone treatment, estrogen or progesterone receptor status, number of documented sites of metastases and individual metastatic sites. Figure 1 shows the Kaplan-Meier estimates of the survivorship function for both OS and PFS for the total patient population (n = 46). Median OS was 24.9 months (95% CI: 15.8-28.1) and median time to progression (PFS) was 10.6 months (95% CI: 8.3-12.8). The mean value of HER-2 expression in plasma samples from 10 healthy female donors was 2377 ± 443 U/ml (mean ± s.d.). Cut-points using the normal mean plasma HER-2 values Ϯ 1 or 2 s.d. (2820 U/ml or 3262 U/ml, respectively) each defined two groups of women whose survival was significantly different (P values of 0.05 and, 0.02 for OS and 0.03 and, 0.04 for PFS, respectively for the two cut-points). Further, a value of 2500 U/ml was determined to be the optimum cut-point for HER-2 overexpression. This value gave the best separation between subgroups of good and poor prognosis. Twenty patients (43.5%) had plasma HER-2 levels higher than 2500 U/ml and were designated as HER-2-positive. Highly significant differences in OS (P Ͻ 0.01) and PFS (P Ͻ 0.01) were observed using this value and it was therefore used for all further analysis. For disease progression, the unadjusted HR (hazard ratio or relative risk) for HER-2 positive status was 2.3 (95% CI: 1.2-4.4). For death, the unadjusted HR for HER-2-positive status was 2.36 (95% CI: 1.2-4.6) ( Table 2) . Figure 2a and b show the Kaplan-Meier survival curves for PFS and OS for patients with high and low expression levels of HER-2. Median overall survival for the n = 20 patients with high HER-2 levels (Ͼ2500 U/ml) was 15.9 months (range 7.6 to 54.5 months) and the median survival time for the n = 26 patients with low HER-2 levels (Ͼ2500 U/ml) was 29.8 months (range 4.8 to 63.0 months). Disease progression (PFS) was also significantly shorter (P Ͻ 0.01) for patients with high levels of circulating HER-2, than for patients with low HER-2 levels (8.6 months, range 1.6 to 22.1 vs 13.0 months, range 4.6 to 63.0 months).
HER-2 expression levels in plasma and survival
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There were no significant differences at the 5% level for OS and PFS based on estrogen or progesterone receptor positive status. Patients with HER-2 positive status, increased number of metastatic sites, or the presence of liver metastases had significantly shorter time to disease progression. HER-2 positive status or the presence of liver or lung metastases resulted in significantly decreased overall survival (Table 3) .
Multivariable analysis
HER-2 status (positive or negative), number of metastatic sites and presence of liver metastases were entered into a Cox proportional hazards model for PFS.
Only HER-2 status remained significant with an adjusted HR of 2.3 (95% CI: 1.2-4.3). Only HER-2 status significantly predicted disease progression (P = 0.01). The rate of disease progression was 2.3 times greater for patients with HER-2 positive status compared to patients with HER-2 negative status (Table 4) .
HER-2 status, liver metastasis and lung metastasis, were entered into a Cox proportional hazards model for OS. Analysis determined that two variables remained significant. Multivariable analysis showed that both lung metastases (HR = 2.4; 95% CI: 1.2-4.7; P = 0.01) and HER-2 status (HR 2.5; 95% CI: 1.2-4.9; P = 0.01) contribute to a model predicting for overall survival (Table 4) . Patients with HER-2-positive status were at risk of dying at a rate of 2.5 times greater than patients with HER-2-negative status after controlling for the presence of liver and lung metastases. Additionally, patients with lung metastases were at risk of dying at a rate of 2.4 times greater than patients without lung metastases after controlling for the presence of HER-2 and liver metastases.
Discussion
Although many factors contribute to chemosensitivity of breast cancers in vitro, only recently have clinical studies begun to determine the contribution of these factors to responses and outcomes of specific treatment regimens for metastatic breast cancer. Clinical studies have shown a substantial association between HER-2 status and disease outcome. Further, recent data suggest that the level of HER-2 expression may not only be a prognostic factor, but may also predict response to different treatments. [6] [7] [8] 16, 17 The prognosis of patients with metastatic breast cancer is very poor with less than 5% surviving 10 years after detection of metastasis. 18 As a result, the main objective of treatments HER-2 optimum cut-point used was 2500 U/ml.
for patients with metastatic breast cancer is to control disease symptoms in order to maximize the quality and duration of remaining life. Survival of patients with metastatic breast cancer is increased only marginally using different cytotoxic therapies. Even some of the newer chemotherapeutic drugs such as the taxanes, have been shown to improve response rates, but not survival for these patients.
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Studies examining HER-2 status in patients with metastatic breast cancer indicate that patients whose tumors The median time to disease progression was 13.0 months for patients (n = 26) with low levels of HER-2 (HER-2 neg Ͻ2500 U/ml) and 8.6 months for patients (n = 20) with high levels of HER-2 (HER-2 pos у2500 U/ml). The survival differences were significant (P Ͻ 0.01). (b) Kaplan-Meier estimates of overall survival (OS) based on HER-2 status following HDCT and ABSCT treatment of patients with metastatic breast cancer. The median time to death was 29.8 months for patients (n = 26) with low levels of HER-2 (HER-2 neg Ͻ2500 U/ml) and 15.9 months for patients (n = 20) with high levels of HER-2 (HER-2 pos у2500 U/ml). The survival differences were significant (P Ͻ 0.01).
overexpress HER-2 have a poorer response to metastatic hormonal therapy. [4] [5] [6] Other studies have shown that patients with high levels of HER-2 have significantly poorer progression-free and overall survival using either high-dose chemotherapy, 7, 8 or standard chemotherapy. 6 These results suggest that it is important to evaluate HER-2 levels in treatment trials for breast cancer to determine appropriate therapy. Further identification of prognostic and/or predictive factors that contribute to outcome in patients with metastatic breast cancer could provide useful insight in determining treatment profiles.
The median overall survival of the total patient group (n = 46) examined in this study using paclitaxel in the highdose regimen was found to be 24.9 months. This is similar to our previous results 7 and those of others for the survival n = 39 and 37 for estrogen receptor and progesterone receptor, respectively. For all other variables, n = 46. The analysis groups for number of metastatic sites was 1 and NED vs 2 or more. P values and 2 were derived using the log-rank test for equality of survivor functions. of patients with metastatic breast cancer using HDCT or conventional chemotherapy. Stadtmauer et al 19 showed that the median overall survival was not statistically different for patients following HDCT consisting of cyclophosphamide, carboplatin and thiotepa compared to the conventional chemotherapy group (24 months vs 26 months). The median overall survival for patients with metastatic breast cancer in a previous study by Bewick et al 7 was 25.1 months following a HDCT treatment regimen of cyclophosphamide, mitoxantrone and carboplatin or vinblastine. Median progression-free survival times were also similar for all of these studies. Although the similarities in length of survival times in these studies are interesting, none of these studies was designed nor intended to assess the effects of treatment differences. Larger randomized controlled phase III trials are necessary. Also studies evaluating patient HER-2 levels within these phase III trials would be of benefit. Studies using HDCT regimens suggest that HER-2 overexpression is a negative predictor for disease progression and overall survival in patients with high risk primary breast cancer (HRPBC) and metastatic breast cancer. 7, 8, 20 The results from this study also suggest that patients with metastatic breast cancer and high soluble plasma HER-2 have a significantly poorer overall and progression-free survival following high-dose chemotherapy with paclitaxel and autologous stem cell support. The median OS of patients with low levels of HER-2 was significantly longer than the median OS of patients with high levels of HER-2 (29.8 vs 15.9 months, P Ͻ 0.01). Some of the cytotoxic drugs used in this study were epirubicin, mitoxantrone, and paclitaxel. These drugs have been shown to be effective in patients with metastatic breast cancer but less effective in patients who overexpress HER-2. [21] [22] [23] [24] [25] Therefore, it may be necessary to use more strategic anti-HER-2-specific therapies to improve survival in this group of patients. Recently, some improvements in survival of patients have been observed in phase II and III clinical trials using trastuzamab (rhuMAb HER-2V, herceptin; Hoffman Laroche, Mississauga, Ontario, Canada), a recombinant humanized anti-HER-2 monoclonal antibody in combination with other chemotherapeutic agents. Herceptin, in combination with paclitaxel, has been shown to improve 1-year survival, OS, time to disease progression, response rate, and duration of response in patients with metastatic breast cancer who show overexpression of HER-2. 26 Univariate analysis of the current data showed that patients with liver or lung metastases had significantly shorter OS and PFS. Patients with metastases to two or more sites also resulted in a significantly reduced time to disease progression, but not OS. Estrogen and progesterone receptor status did not predict for differences in survival at the 5% level.
In multivariable analysis, lung metastases contributed to the model along with HER-2-positive status to determine a group of patients with significantly poorer OS. However, HER-2-positive status remained the only independent predictor of PFS.
In this study, 43.5% of patients with metastatic breast cancer had elevated levels of plasma HER-2 as defined by the optimum cutpoint. This optimum cutpoint for HER-2 overexpression was less than that concentration determined by the mean value plus 1 s.d. in the plasma of 10 healthy women (2820 U/ml). This may be due to the fact that only a small group of healthy patients were used resulting in a large standard deviation.
Results of others have shown high expression levels of HER-2 in high risk primary and metastatic breast cancer patients using immunohistochemical analysis of paraffinembedded tumor sections, FISH analysis for HER-2 gene amplification, and EIA analysis of secreted HER-2 in patient plasma. [27] [28] [29] [30] Presently, there is no 'best method' to test for HER-2 overexpression. Although immunohistochemistry and FISH are the most often used clinical methods of testing, the requirement for primary and/or metastatic tumor tissue can be a disadvantage. Some results indicate that the HER-2 status of a patient may change over time. 7, 31, 32 HER-2 amplification/overexpression may not be detected until the disease progresses from a hormonedependent to a hormone-independent phenotype. 31 As a result, sampling for analysis of HER-2 levels over time by these methods may be more difficult, time-consuming, and expensive than a simple EIA method using plasma or serum. Circulating HER-2 levels have been shown to correlate with increasing tumor burden in metastatic breast cancer and may be more easily detectable in this group of patients and recent results indicate that this method of analysis (using serum or saliva) may be sensitive enough to be potentially useful in assisting in the initial detection and follow-up of breast cancer patients. 33 The ability of immunohistochemical analysis to predict for disease prognosis has been inconsistent. 6 This is probably due to wide variety of differences in samples (fresh, archival), techniques, HER-2 antibodies and subjective interpretations between studies. 6, 25, 30 Results of analysis of HER-2 levels using different methods are not always similar. For example, response rates to a combined regimen of paclitaxel with trastuzamab has been shown to vary by up to 20% depending on whether immunohistochemistry or FISH analyses are used to assess HER-2 levels. 25 The results of Colomer et al 27 suggest that circulating HER-2 levels may be a better indicator of resistance to chemotherapy for patients with metastatic breast cancer than the expression of HER-2 in the primary tumor. Elevated levels of circulating HER-2 in the serum of advanced breast cancer patients correlated inversely with the response to paclitaxel-doxorubicin chemotherapy treatment. 27 Future randomized prospective studies examining the correlation between plasma HER-2 levels (EIA method) and cellular HER-2 expression (by FISH and immunohistochemistry) would be useful to determine which test(s) most reliably predict outcome and response to treatment, particularly in clinical trials using trastuzamab treatment.
More definitive answers to questions regarding the survival benefit of HDCT and ASCT in patients with metastatic and high-risk primary breast cancer are needed. These will have to await the final results of randomized clinical trials in 1 to 2 years. [34] [35] [36] Analysis of HER-2 levels of samples from these larger clinical trials may define clinically meaningful and statistically significant differences in responses (predictive power) and survival (prognostic power) for a subgroup of patients who can benefit the most from this treatment.
